Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03161301 · ClinicalTrials.gov registry record
Role of IL-37 Genetic Variants in Modulating Innate Immune Response to Periodontal Pathogens
A clinical trial, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- 86
- Enrollment target
NCT03161301: Completed study, sponsored by University of North Carolina, Chapel Hill.
NCT03161301 is a clinical trial that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 86 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03161301 has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- 86 participants
- Enrollment target
Study Summary
This study will provide mechanistic insight into the underlying causes and molecular level pathogenesis of periodontal diseases. We will identify key mechanisms that confer risk and protection. Ultimately this will lead to new and improved diagnostics and therapeutics. Because periodontal disease is a uniquely accessible biofilm-associated disease it will provide insight into many other diseases such as inflammatory bowel disease and chronic infections associated with indwelling catheters and artificial prostheses. Subjects with periodontal conditions will have therapeutic benefit from the treatments provided.
Primary Outcome
Levels of key cytokines in gingival crevicular fluid.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2015-05-07 |
| Est. Completion | 2019-05-24 |
What the finished NCT03161301 record still lists
NCT03161301 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 86 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT03161301 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03161301 about?
NCT03161301 is a clinical study titled "Role of IL-37 Genetic Variants in Modulating Innate Immune Response to Periodontal Pathogens". This study will provide mechanistic insight into the underlying causes and molecular level pathogenesis of periodontal diseases. We will identify key mechanisms that confer risk and protection. Ultimately this will lead to new and improved diagnostics and therapeutics. Because periodontal disease is...
What is the current status of trial NCT03161301?
This trial is currently completed. The enrollment target is 86 participants. The study started on 2015-05-07. Estimated completion is 2019-05-24.
Who is sponsoring clinical trial NCT03161301?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01639508 · 86 participants · Phase 2
Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
- NCT03519269 · 86 participants · NA
Navio Robotic Versus Conventional Total Knee Arthroplasty
- NCT04132999 · 86 participants · NA
PAP for Children With DS and OSAS
- NCT04545957 · 86 participants · NA
Jump: MR Simulation For Radiation Therapy Master Protocol
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI